But what does the scientific research actually show?
This article reviews the current evidence — separating laboratory science from human clinical data — and explains what breast cancer patients should know before considering fenbendazole.
- You are here:
- Home »
- Blog »
- lymphoma »
- Fenbendazole and Lymphoma
Fenbendazole and Lymphoma
Fenbendazole and Lymphoma — Separating Hope from Hype. In recent years, fenbendazole (often shortened to “fenben”) has gained attention online as a possible alternative cancer therapy. Stories circulating on social media claim dramatic responses in various cancers, including lymphoma.
I am a long-term survivor of an incurable blood cancer called multiple myeloma. I have gone to great lengths beyond conventional, FDA-approved therapies and taken great risks in an effort to manage my blood cancer. I can understand why cancer patients hear about non-conventional therapies and want to understand more about them as possible therapies.
The post below is PeopleBeatingCancer’s effort to weigh in on the fenben and lymphoma debate. Please scroll down the page, post a question or a comment if you have any questions.
Thank you,
David Emerson
- Cancer Survivor
- Cancer Coach
- Director PeopleBeatingCancer
What Is Fenbendazole?
Fenbendazole is a benzimidazole antiparasitic drug widely used in veterinary medicine to treat worms in animals. It disrupts microtubules in parasites, impairing cell division — a mechanism similar to some chemotherapy drugs. However, fenbendazole is not approved for treating cancer in humans by regulating authorities such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA).
Why People Talk About Fenbendazole for Cancer
In recent years, health blogs and social media posts have promoted fenbendazole as a potential anticancer treatment. This interest stems from laboratory research showing that fenbendazole can kill or slow the growth of some cancer cells in petri dishes and animal models.
How Fenbendazole Could Treat Cancer (and Why It Won’t)
Lymphoma and What Research Shows
Lymphoma is a type of cancer that begins in immune cells called lymphocytes. Because some microtubule-targeting drugs are effective in lymphoma treatment, scientists have examined whether fenbendazole might have similar activity.
Preclinical Evidence
In lab studies, fenbendazole has shown some ability to:
- cause lymphoma cells in culture to arrest in the cell cycle and undergo programmed cell death, similar to some chemotherapy agents.
However, when researchers tested fenbendazole in animal models of lymphoma, the results did not show meaningful anticancer effects:
- A T-cell lymphoma model in mice treated with fenbendazole did not exhibit slower tumor growth compared to control animals.
Another earlier animal study with a human lymphoma cell line suggested that fenbendazole alone did not reduce tumor growth, though when combined with vitamins, it appeared to reduce tumor progression. Importantly, the role of fenbendazole in that effect was not isolated, and vitamins themselves have known biological activity.
Limits of Current Evidence
- All of the strongest data about fenbendazole and lymphoma come from preclinical research — meaning cell lines or animal models.
- There are no large, high-quality clinical trials in humans showing that fenbendazole is effective or safe for treating lymphoma.
Risks of Unsupervised Use
Fenbendazole is not formulated for humans, and it is poorly absorbed orally. Some anecdotal reports suggest people who took veterinary fenbendazole experienced liver toxicity or interactions with other medications.
Using unproven treatments without medical supervision can:
- Delay proven therapies
- Cause harmful side effects
- Interfere with standard cancer treatments
Patients should discuss any off-label or experimental therapy with their oncologist.
Fenbendazole and Lymphoma
- Dogra N, et al. Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways. Sci Rep. 2018;8:11926.
https://pubmed.ncbi.nlm.nih.gov/30072706/ - Bai R, et al. Interactions of benzimidazole anthelmintics with tubulin: structural basis for antimitotic activity. Biochemistry. 1991;30(17):4438-4447.
https://pubmed.ncbi.nlm.nih.gov/2018774/ - Jung H, et al. Fenbendazole treatment does not alter tumor growth in a murine T-cell lymphoma model. J Vet Sci.2023.
https://pubmed.ncbi.nlm.nih.gov/37734188/ - Mukhopadhyay T, et al. Benzimidazoles destabilize microtubules and enhance p53 activity in tumor models. Cancer Res. 2002;62(19):5683-5688.
https://pubmed.ncbi.nlm.nih.gov/12384519/ - Duong F, et al. Anthelmintic benzimidazoles inhibit mitochondrial function and induce apoptosis in cancer cells. Mol Cancer Ther. 2006;5(2):362-370.
https://pubmed.ncbi.nlm.nih.gov/16505115/
Fenbendazole and Lymphoma Fenbendazole and Lymphoma Fenbendazole and Lymphoma